Details

Dr. Harshad Padmanabh Patil

Profile

Profile

Date of Birth: 12.08.1984

Qualification: PhD

Designation: Associate Professor

Contacts

e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: +919130551560

Academic Qualifications:

Degree Year Institution and Location Major Subjects
Medical Sciences (Vaccinology) 2014 University Medical Center Groningen, University of Groningen, The Netherlands Doctorate in Philosophy (Ph.D.)
Virology 2007 National Institute of Virology, University of Pune, India Master of Science (M. Sc.)
Microbiology 2005 Bachelor of Science (B. Sc.), Abasaheb Garware College, University of Pune, India

Research Interest:

Viral vaccines and immunology.

Research experience:

Post doctoral research fellow, Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium (June 2014 – June 2016).

  • Evaluation of the residence time and efficacy of PEGylated monoclonal antibodies (anti-IL13 or anti-IL17) after pulmonary delivery.
  • Analysis of B and T cell immune mechanisms elicited by AdvaxTM- adjuvanted inactivate whole influenza virus vaccine administered by different immunization strategies.
  • Evaluation of immune response elicited by influenza subunit or hepatitis B surface antigen vaccine after delivery to various sites within the lung.

Ph.D. fellow, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands (November 2009 – February 2014)

    • Evaluation of physical and immunogenic stability of spray freeze dried influenza vaccine powder for pulmonary delivery.
    • Comparison of adjuvants for the development of spray freeze dried whole inactivated virus vaccine for pulmonary delivery.
    • Evaluation of GPI-0100 as mucosal adjuvant for inactivated influenza vaccines.

Industrial experience

    • Quality control, Serum Institute of India Ltd, Pune, India, December 2007-October 2009
    • Production trainee, Ventri Biologicals, Pune, India, August 2007-December 2007.

Honors and awards

  • Best poster presentation award at 3rd International conference on lung health, 2016, Monaco
  • TRANSVAC course, 2013. Got selected and participated at ‘Practical approaches to vaccine development’ by European Vaccine Initiative, Lausanne, Switzerland.
  • Jan Kornelis de Cock grant, 2012, University of Groningen, The Netherlands (Grant to purchase experimenal materials).
  • Ubbo Emmius Ph.D. Scholarship, 2009, University of Groningen, The Netherlands (Four year grant to execute self-designed Ph.D. project)

Publications

  • PEGylation of paclitaxel largely improves its safety an anti tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma. Luo T, Loira-Pastoriza C, Patil HP, Ucakar B, Muccioli GG, Bosquillon C, Vanbever R. J Control Release. 2016 Aug 8;239:62-71, impact factor: 7.41 http://www.ncbi.nlm.nih.gov/pubmed/27515664 2.
  • Comparison of adjuvants for the development of spray freeze dried whole inactivated virus vaccine for pulmonary delivery Patil HP, Murugappan S, de Vries-Idema J, Meijerhof T, de Haan A, Frijlink HW, Wilschut J, Hinrichs WL, Huckriede A Eur J Pharm Biopharm. 2015 Jun;93:231-41, impact factor: 3.97 http://www.ncbi.nlm.nih.gov/pubmed/25896446
  • Simplifying influenza vaccination during pandamics: Sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine Murugappan S, Patil HP, Frijlink HW, Huckriede A, Hinrichs WL. AAPS J. 2014 Mar;16(2):342-9, impact factor: 3.79 http://www.ncbi.nlm.nih.gov/pubmed/24482005 4.
  • Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine Patil HP, Murugappan S, ter Veer W, Meijerhof T, de Haan A, Frijlink HW, Wilschut J, Hinrichs WL, Huckriede A. J Control Release. 2014 Jan 28;174:51-62., impact factor: 7.41 http://www.ncbi.nlm.nih.gov/pubmed/24269505 5.
  • Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A. PLoS One. 2013 Jul 31;8 (7):e69649, impact factor: 3.2 http://www.ncbi.nlm.nih.gov/pubmed/23936066 6.
  • Physical and immunogenic stability of spray freeze dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran or a mixture of dextran and trehalose as protectants Murugappan S*, Patil HP*, Kanojia G, ter Veer W, Meijerhof T, Frijlink HW, Huckriede A, Hinrichs WL. Eur J Pharm Biopharm. 2013 Nov; 85 (3PtA):716-25, impact factor: 3.97 http://www.ncbi.nlm.nih.gov/pubmed/23933147 7.
  • Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100 Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A. PLoS One. 2012;7(12):e52135, impact factor: 3.2 http://www.ncbi.nlm.nih.gov/pubmed/23284901
  • Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation. Patil HP, Herrera Rodriguez J, de Vries-Idema J, Meijerhof T, Frijlink HW, Hinrichs WLJ, Huckriede A*. Vaccines (Basel). 2017 Jul 27;5(3) https://www.ncbi.nlm.nih.gov/pubmed/28749414
  • Production and characterization of a PEGylated derivative of recombinant human deoxyribonuclease I for cystic fibrosis therapy. Guichard MJ, Patil HP, Koussoroplis SJ, Wattiez R, Leal T, Vanbever R*. International journal of pharmaceutics. 2017 May 30;524(1-2):159-167, impact factor: 3.6 https://www.ncbi.nlm.nih.gov/pubmed/28356227
  • PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab' antibody fragment after pulmonary delivery in three different species. Freches D, Patil HP, Machado Franco M, Uyttenhove C, Heywood S, Vanbever R*. International journal of pharmaceutics. 2017 Feb 10;521(1-2):120-129, impact factor: 3.6 https://www.ncbi.nlm.nih.gov/pubmed/28192159

International conference and workshop

Oral presentation:

  • Impact of PEGylation on biodistribution and efficacy of antibody fragments after pulmonary delivery, Therapeutic monoclonal antibodies for respiratory research, 2016, Tours, France
  • Comparison of adjuvants for the development of spray freeze dried whole inactivated virus vaccine for pulmonary delivery, Vaccine symposium, 2013, Utrecht, The Netherlands

Poster presentation:

  • Impact of the delivery site of antibody fragments within the lung on their local residence time, Dutch-Belgium biopharmacy day, 2015, Leuven, Belgium and 3rd International conference on lung health, 2016, Monaco
  • Postdoctoral Advisor: Dr. Ratna B. Ray, Professor, Department of Pathology, Edward A Doisy Research Center, RM 207, Saint Louis University, 1100 South Grand Blvd., Saint Louis, MO, 63104, USA. Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Spray freeze-dried monophosphoryl lipid A-adjuvanted whole inactivated virus influenza vaccine induces effective humoral responses against influenza virus after pulmonary vaccination. 4th Influenza vaccines for the world, 2012, Valencia, Spain
  • Pulmonary administration of monophosphoryl lipid A-adjuvanted whole inactivated virus influenza vaccine formulated as dry powder successfully induces IgA and IgG , 4th ESWI influenza conference, 2011, Malta

Participation

  • 7th European Mucosal Immunology group meeting (EMIG), 2010, Amsterdam, The Netherlands
  • Dutch-Belgium biopharmacy day, 2014, Rotterdam, The Netherlands